GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relypsa Inc (NAS:RLYP) » Definitions » Asset Turnover

Relypsa (Relypsa) Asset Turnover : 0.02 (As of Jun. 2016)


View and export this data going back to 2013. Start your Free Trial

What is Relypsa Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Relypsa's Revenue for the three months ended in Jun. 2016 was $5.22 Mil. Relypsa's Total Assets for the quarter that ended in Jun. 2016 was $291.48 Mil. Therefore, Relypsa's Asset Turnover for the quarter that ended in Jun. 2016 was 0.02.

Asset Turnover is linked to ROE % through Du Pont Formula. Relypsa's annualized ROE % for the quarter that ended in Jun. 2016 was -226.64%. It is also linked to ROA % through Du Pont Formula. Relypsa's annualized ROA % for the quarter that ended in Jun. 2016 was -114.75%.


Relypsa Asset Turnover Historical Data

The historical data trend for Relypsa's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relypsa Asset Turnover Chart

Relypsa Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15
Asset Turnover
- - - - 0.09

Relypsa Quarterly Data
Dec11 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.02 0.04 0.05 0.02

Competitive Comparison of Relypsa's Asset Turnover

For the Biotechnology subindustry, Relypsa's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relypsa's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relypsa's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Relypsa's Asset Turnover falls into.



Relypsa Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Relypsa's Asset Turnover for the fiscal year that ended in Dec. 2015 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2015 )/( (Total Assets (A: Dec. 2014 )+Total Assets (A: Dec. 2015 ))/ count )
=18.55/( (151.839+278.328)/ 2 )
=18.55/215.0835
=0.09

Relypsa's Asset Turnover for the quarter that ended in Jun. 2016 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Jun. 2016 )/( (Total Assets (Q: Mar. 2016 )+Total Assets (Q: Jun. 2016 ))/ count )
=5.221/( (261.384+321.577)/ 2 )
=5.221/291.4805
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Relypsa  (NAS:RLYP) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Relypsa's annulized ROE % for the quarter that ended in Jun. 2016 is

ROE %**(Q: Jun. 2016 )
=Net Income/Total Stockholders Equity
=-334.464/147.577
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-334.464 / 20.884)*(20.884 / 291.4805)*(291.4805/ 147.577)
=Net Margin %*Asset Turnover*Equity Multiplier
=-1601.53 %*0.0716*1.9751
=ROA %*Equity Multiplier
=-114.75 %*1.9751
=-226.64 %

Note: The Net Income data used here is four times the quarterly (Jun. 2016) net income data. The Revenue data used here is four times the quarterly (Jun. 2016) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Relypsa's annulized ROA % for the quarter that ended in Jun. 2016 is

ROA %(Q: Jun. 2016 )
=Net Income/Total Assets
=-334.464/291.4805
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-334.464 / 20.884)*(20.884 / 291.4805)
=Net Margin %*Asset Turnover
=-1601.53 %*0.0716
=-114.75 %

Note: The Net Income data used here is four times the quarterly (Jun. 2016) net income data. The Revenue data used here is four times the quarterly (Jun. 2016) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Relypsa Asset Turnover Related Terms

Thank you for viewing the detailed overview of Relypsa's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Relypsa (Relypsa) Business Description

Traded in Other Exchanges
N/A
Address
Relypsa Inc is a biopharmaceutical company engaged in the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases.
Executives
Ronald A. Krasnow officer: See Remarks C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Kristine M Ball officer: Chief Financial Officer & SVP C/O RELYPSA, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Mcgirr David W J director 33 PHEASANT LANE, GREENWICH CT 06830
Paul J Hastings director 61 HARTFORD STREET, SAN FRANCISCO CA 94114
John A Orwin director, officer: President & CEO C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Kenneth J. Hillan director C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Wilhelm Stahl officer: SVP, Chief Technology Officer C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
J. Scott Garland officer: SVP & Chief Commercial Officer 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
John P. Butler director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Helen Torley director C/O ONYX PHARMACEUTICALS, INC., 249 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
James D Dondero 10 percent owner 300 CRESCENT COURT, SUITE 700, DALLAS TX 75201
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Samuel D Isaly 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Iv Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022

Relypsa (Relypsa) Headlines

From GuruFocus

Insiders Buy Stock in Wynn Resorts, Bank of New York Mellon

By Tiziano Frateschi Tiziano Frateschi 10-26-2015